黑料网

STOCK TITAN

Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags

Park Ha Biological Technology (Nasdaq: PHH) has successfully completed its Initial Public Offering, raising $4.8 million through the sale of 1,200,000 ordinary shares at $4.00 per share. Trading began on the Nasdaq Capital Market on December 27, 2024, under the symbol 'PHH'.

The company, which specializes in private skincare labels, direct sales, and franchise alliance promotions, has granted underwriters a 45-day option to purchase up to 180,000 additional shares. The net proceeds will be used to expand directly-owned stores in China, purchase product patents for proprietary development, and acquire ingredient suppliers to reduce production costs.

Dawson James Securities and D. Boral Capital served as underwriters for this firm commitment offering.

Park Ha Biotechnologia (Nasdaq: PHH) ha completato con successo la sua Offerta Pubblica Iniziale, raccogliendo 4,8 milioni di dollari tramite la vendita di 1.200.000 azioni ordinarie al prezzo di 4,00 dollari per azione. Le contrattazioni sono iniziate sul Nasdaq Capital Market il 27 dicembre 2024, sotto il simbolo 'PHH'.

L'azienda, specializzata in etichette di skincare private, vendite dirette e promozioni alleanze in franchising, ha concesso ai sottoscrittori un'opzione di acquisto per 45 giorni che consente di acquistare fino a 180.000 azioni aggiuntive. I proventi netti saranno utilizzati per ampliare i negozi di propriet脿 in Cina, acquistare brevetti di prodotto per lo sviluppo proprietario e acquisire fornitori di ingredienti per ridurre i costi di produzione.

Dawson James Securities e D. Boral Capital hanno svolto il ruolo di sottoscrittori per questa offerta di impegno fermo.

Park Ha Biotecnolog铆a (Nasdaq: PHH) ha completado con 茅xito su Oferta P煤blica Inicial, recaudando 4,8 millones de d贸lares a trav茅s de la venta de 1.200.000 acciones ordinarias a 4,00 d贸lares por acci贸n. La negociaci贸n comenz贸 en el Nasdaq Capital Market el 27 de diciembre de 2024, bajo el s铆mbolo 'PHH'.

La empresa, que se especializa en etiquetas de cuidado de la piel privadas, ventas directas y promociones de alianzas de franquicias, ha otorgado a los suscriptores una opci贸n de compra de 45 d铆as para adquirir hasta 180.000 acciones adicionales. Los ingresos netos se utilizar谩n para expandir tiendas de propiedad directa en China, comprar patentes de productos para desarrollo propio y adquirir proveedores de ingredientes para reducir los costos de producci贸n.

Dawson James Securities y D. Boral Capital actuaron como suscriptores para esta oferta de compromiso firme.

Park Ha 靸濍獏瓿淀暀 旮办垹 (Nasdaq: PHH)臧 靹标车鞝侅溂搿 靸侅灔瓿惦毳 鞕勲頃橃榾鞙茧┌, 480毵 雼煬毳 氇笀頃橃榾鞀惦媹雼. 鞚措姅 欤茧嫻 4.00 雼煬搿 1,200,000欤茧ゼ 韺愲Г頃 瓴瓣臣鞛呺媹雼. 瓯半灅電 2024雲 12鞗 27鞚 Nasdaq 鞛愲掣鞁滌灔鞐 'PHH' 旮绊樃搿 靸侅灔霅橃棃鞀惦媹雼.

鞚 須岇偓電 臧滌澑 鞀ろ偍旒鞏 敫岆灉霌, 歆侅爲 韺愲Г 氚 頂勲灉彀澊歃 鞝滍湸 頂勲氇厴鞚 鞝勲鞙茧 頃橂┌, 鞚胳垬鞛愲摛鞐愱矊 180,000欤检潣 於旉皜 毵れ瀰鞚 鞙勴暅 45鞚 鞓奠厴鞚 攵鞐枅鞀惦媹雼. 靾滌垬鞚奠潃 欷戧淡鞐愳劀 歆侅榿 毵れ灔 頇曥灔, 霃呾爯 臧滊皽鞚 鞙勴暅 鞝滍拡 韸鬼棃 甑Г, 靸濎偘 牍勳毄 鞝堦皭鞚 鞙勴暅 鞗愲 瓿店笁鞐呾泊 鞚胳垬鞐 靷毄霅 鞓堨爼鞛呺媹雼.

Dawson James Securities鞕 D. Boral Capital鞚 鞚 頇曥爼 瓿惦鞚 鞚胳垬鞛 鞐暊鞚 靾橅枆頄堨姷雼堧嫟.

Park Ha Biotechnologie (Nasdaq: PHH) a r茅ussi 脿 terminer son Offre Publique Initiale, en levant 4,8 millions de dollars gr芒ce 脿 la vente de 1.200.000 actions ordinaires au prix de 4,00 dollars par action. Les 茅changes ont commenc茅 sur le Nasdaq Capital Market le 27 d茅cembre 2024, sous le symbole 'PHH'.

La soci茅t茅, qui se sp茅cialise dans les 茅tiquettes de soins de la peau priv茅es, les ventes directes et les promotions d'alliances en franchise, a accord茅 aux souscripteurs une option d'achat de 45 jours pour acqu茅rir jusqu'脿 180.000 actions suppl茅mentaires. Les produits nets seront utilis茅s pour 茅largir les magasins en propri茅t茅 directe en Chine, acheter des brevets de produits pour le d茅veloppement propri茅taire, et acqu茅rir des fournisseurs d'ingr茅dients pour r茅duire les co没ts de production.

Dawson James Securities et D. Boral Capital ont agi en tant que souscripteurs pour cette offre d'engagement ferme.

Park Ha Biotechnologie (Nasdaq: PHH) hat erfolgreich ihr Initial Public Offering abgeschlossen und 4,8 Millionen Dollar durch den Verkauf von 1.200.000 Stammaktien zu 4,00 Dollar pro Aktie gesammelt. Der Handel begann am 27. Dezember 2024 an der Nasdaq Capital Market unter dem Symbol 'PHH'.

Das Unternehmen, das sich auf private Hautpflegeetiketten, Direktvertrieb und Franchise-Allianzen spezialisiert hat, hat den Underwritern eine 45-t盲gige Option einger盲umt, um bis zu 180.000 zus盲tzliche Aktien zu erwerben. Die Nettoerl枚se werden verwendet, um direkt owned Gesch盲fte in China auszubauen, Produktpatente f眉r die eigene Entwicklung zu erwerben und Lieferanten von Zutaten zu akquirieren, um Produktionskosten zu senken.

Dawson James Securities und D. Boral Capital fungierten als Underwriter f眉r dieses feste Angebot.

Positive
  • Successful IPO raising $4.8 million in gross proceeds
  • Nasdaq Capital Market listing achieved
  • Strategic plan to expand retail presence in China
  • Vertical integration strategy through ingredient supplier acquisitions
  • 45-day option for additional 180,000 shares granted to underwriters
Negative
  • Relatively small IPO size of $4.8 million
  • Potential dilution if underwriters exercise their option for additional shares

Insights

Park Ha Biological Technology's $4.8 million IPO represents a relatively small public offering in the cosmetics and skincare sector. The $4.00 per share pricing and 1.2 million share offering indicates cautious market entry positioning. The company's three-pronged strategy for utilizing proceeds - expanding direct stores, acquiring patents and vertically integrating through supplier acquisitions - demonstrates a comprehensive growth approach. The firm commitment underwriting structure provides more certainty compared to best-efforts offerings, though the modest size suggests institutional interest. The 45-day overallotment option of 180,000 additional shares provides flexibility for price stabilization post-IPO. The choice of smaller investment banks (Dawson James and D. Boral) as underwriters aligns with the offering size but may impact broader market awareness and trading liquidity.

The Chinese skincare market context is important for evaluating this IPO. With a $106.6 million market cap, Park Ha positions itself in the growing private label segment, which has seen increased demand due to rising consumer sophistication and cost-consciousness in China. The company's focus on direct sales and franchise alliances suggests a hybrid distribution model that could potentially optimize margins. The vertical integration strategy through supplier acquisition indicates awareness of margin pressure in the competitive skincare market. However, the relatively small capital raise may limit execution speed and scale compared to larger competitors. The timing of the IPO during year-end could affect initial trading dynamics due to typically lower market volumes.

The capital structure implications of this IPO warrant attention. The 15% greenshoe option is standard but notable given the small float. Working capital deployment will be critical - balancing store expansion (high capex) with patent acquisitions (potentially immediate revenue impact) requires precise execution. The listing on Nasdaq provides access to U.S. capital markets, though the small float may result in higher volatility. Investors should monitor the post-IPO lock-up period and potential insider selling pressure. The vertical integration strategy through supplier acquisition could improve gross margins, but integration risks and capital requirements need careful management. The moderate offering size suggests a conservative approach to public market exposure while maintaining founder control.

Wuxi, China, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) (the 鈥淐ompany鈥), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the closing of its initial public offering (the 鈥淥ffering鈥) of 1,200,000 ordinary shares (the 鈥淥rdinary Shares鈥) at a public offering price of $4.00 per ordinary share. The Ordinary Shares began trading on the Nasdaq Capital Market on December 27, 2024 under the ticker symbol 鈥淧HH.鈥

The Company received aggregate gross proceeds of $4.8 million from the Offering, before deducting underwriting discounts and other related expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to 180,000 additional ordinary shares, representing 15% of the ordinary shares sold in the Offering, at the public offering price, less underwriting discounts.

Net proceeds from the Offering will be used for (i) expanding the scale of directly-owned stores in the PRC; (ii) purchasing existing product patents to develop proprietary products; and (iii) acquiring ingredient suppliers to reduce production costs over the long term.

The Offering is being conducted on a firm commitment basis. Dawson James Securities, Inc. and D. Boral Capital LLC acted as underwriters for the Offering (the 鈥淯nderwriters鈥). Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel to the Underwriters in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the 鈥淪EC鈥) (File Number: 333-281783) and was declared effective by the SEC on December 20, 2024. A final prospectus describing the terms of the proposed offering was filed with the SEC and is available on the SEC鈥檚 website at聽. The Offering was made only by means of a prospectus, forming a part of the registration statement. Alternatively, electronic copies of the final prospectus may be obtained by contacting Dawson James Securities, Inc. by standard mail to Dawson James Securities, Inc., 101 N. Federal Highway Suite 600 Boca Raton, Florida 33432, or via email at , or by telephone at +1(561)-391-5555; or from D. Boral Capital LLC by standard mail to D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or via email at , or by telephone +1(212)-970-5150.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only. It shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the Company鈥檚 securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company鈥檚 securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Park Ha Biological Technology Co., Ltd.

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand 鈥淧ark Ha鈥, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of April 30, 2024, the Company has two directly operated stores and 43 franchisees, of which 41 and two operate under the store name 鈥淧ark Ha鈥 and 鈥淕eni鈥 respectively, in China. As part of its value-added service for the products, the Company offers 鈥渓ight beauty experience鈥, a quick complimentary after-sales beauty service performed in the directly-operated stores and franchise stores. For more information, please visit the Company鈥檚 website: .

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥 鈥渂elieves,鈥 鈥渉opes,鈥 鈥渆xpects,鈥 鈥渁nticipates,鈥 鈥渆stimates,鈥 鈥減rojects,鈥 鈥渋ntends,鈥 鈥減lans,鈥 鈥渨ill,鈥 鈥渨ould,鈥 鈥渟hould,鈥 鈥渃ould,鈥 鈥渕ay鈥 or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.

For more information, please contact:

Park Ha Biological Technology Co., Ltd.
Investor Relations Department
Email:

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
贰尘补颈濒:听


FAQ

How much did Park Ha Biological Technology (PHH) raise in its IPO?

Park Ha Biological Technology raised $4.8 million in gross proceeds through its IPO by selling 1,200,000 ordinary shares at $4.00 per share.

When did PHH stock begin trading on Nasdaq?

PHH stock began trading on the Nasdaq Capital Market on December 27, 2024.

What is the underwriters' option in PHH's IPO?

Underwriters have a 45-day option to purchase up to 180,000 additional ordinary shares at the public offering price, representing 15% of the shares sold in the IPO.

How will PHH use its IPO proceeds?

PHH will use the proceeds to expand directly-owned stores in China, purchase product patents for proprietary development, and acquire ingredient suppliers to reduce production costs.

Who were the underwriters for PHH's IPO?

Dawson James Securities, Inc. and D. Boral Capital acted as underwriters for the IPO.

Park Ha Biological Technology Co., Ltd. Ordinary Shares

NASDAQ:PHH

PHH Rankings

PHH Latest News

PHH Stock Data

123.52M
1.20M
82.25%
Household & Personal Products
Consumer Defensive
United States of America
Wuxi